• 02/11/2025, Sophia Antipolis, France

    Disclosure of total number of voting rights and number of shares in the capital as of January 31st, 2025

    Disclosure of total number of voting rights and number of shares in the capital as of January 31st, 2025, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20250211_PR_shares_votingrights_jan2025.pdf
  • 02/05/2025, Sophia Antipolis, France

    Median Technologies gives update on drawdowns of the Iris equity line

    Press release – For immediate release – 5:45 pm CET Median Technologies gives update on drawdowns of the Iris equity line Median Technologies (FR0011049824, ALMDT, PEA/SME scheme eligible), a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnostics, and a globally leading provider of […]
    Read more Download 20250205_PR_IRISstatus_EN-1.pdf
  • 02/03/2025, Sophia Antipolis, France

    eyonis™ Lung Cancer Screening (LCS) meets primary endpoint in RELIVE clinical trial, the final pivotal study required for regulatory submissions

    Top-line data from RELIVE shows that eyonis™ LCS together with radiologist achieved statistically significant improvement over radiologist alone (p=0.027). RELIVE is the second of two pivotal studies required for marketing authorization in U.S. and Europe.
    Read more Download 20250203_PR_RELIVE_topline_EN_Final-2.pdf
  • 01/31/2025, Sophia-Antipolis, France

    Median Technologies reports 2024 key financial indicators and 2025 outlook

    Median Technologies releases today its 2024 key financial indicators (unaudited), and provides an outlook on the Company’s critical milestones in 2025.
    Read more Download 20250131_PR_2024keyfigures_EN.pdf
  • 01/24/2025, Sophia Antipolis, France

    Median Technologies securing up to €47.5 million to support AI lung cancer diagnostic eyonis™ regulatory filings and commercialization in U.S. and EU

    Repayment of 2020 EIB loan to be rescheduled to October 2025 from April, new €37.5 million 2025 EIB loan under appraisal, final authorization stage and new up to €10 million equity line completed with IRIS to enable 2025 EIB loan
    Read more Download 20250124_PR_Refinancing_final_EN.pdf
  • 01/14/2025, Sophia Antipolis, France

    Financial Communications Schedule for the First Half of 2025

    Median Technologies announces the publication date for its 2024 results.
    Read more Download 20250114_PR_H1financialcom_EN.pdf
  • 01/09/2025, Sophia Antipolis, France

    Half year Median Technologies liquidity contract statement

    Under the liquidity contract entrusted by Median Technologies to TP ICAP (Europe), the following resources were listed in the liquidity account as of December 31, 2024: 30,599 shares, €134,615.99 in cash.
    Read more Download 20250109_PR_liquiditycontHY22024_EN.pdf
  • 01/08/2025, Sophia Antipolis, France

    Disclosure of total number of voting rights and number of shares in the capital as of December 31st, 2024

    Disclosure of total number of voting rights and number of shares in the capital as of December 31st, 2024, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20250108_PR_shares_votingrights_Dec2024.pdf
  • 12/11/2024, Sophia Antipolis, France

    Disclosure of total number of voting rights and number of shares in the capital as of November 30th, 2024

    Disclosure of total number of voting rights and number of shares in the capital as of November 30th, 2024, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20241211_PR_shares_votingrights_Nov2024.pdf
  • 11/26/2024, Sophia Antipolis, France

    Median Technologies to showcase AI-powered lung cancer diagnostic eyonis™ LCS at the Radiological Society of North America (RSNA) 2024

    The Company will share the latest developments for eyonis™ Lung Cancer Screening (LCS) Software as a Medical Device (SaMD) as well as the most recent advances for iCRO central and AI-powered oncology trial imaging services for pharmaceutical companies.
    Read more Download 20241126_PR_RSNA2024_EN.pdf
    • 1 … 40